Skip to main content


Clik to enlarge (follow link for pdf)

A Poster presented by Titus Kretzschmar and supported by Delenex Therapeutics AG.

Link to poster

The poster presents DLX1008, a proprietary antibody fragment by Delenex Therapeutics. DLX1008 shows anti-tumor activity in an in-vivo preclinical model of Kaposi sarcoma. Showing advantages over other antibodies, it can now be advanced to clinical trials in Kaposi sarcoma.

Presented at PEGS Summit,
May 3rd – 8th, 2015 in Boston MA.